Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Mar 102014

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. The years 2012, 2013, and 2014 do appear to likely be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.

An article recently posted on the Senesco Technologies web site (https://senesco.com/newsitem.php?id=296; obtained on 3-10-14) began the following way:


In Non-clinical Cancer Studies Senesco’s Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the Active Components of Revlimid® and Velcade® Studies Provide Additional Confirmation That SNS01-T Preferentially Targets Cancer Cells

Bridgewater, N.J. (March 4th, 2014) Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (OTCQB: SNTI) announced the publication in the peer-reviewed journal Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy, of new results from placebo-controlled, non-clinical studies of its therapeutic candidate, SNS01-T, in models of B-cell cancers that show synergy in combination with the active components of Revlimid and Velcade.



‘The synergy demonstrated between SNS01-T and current standard-of-care drugs further emphasizes the therapeutic potential of SNS01-T. We are excited by these results since there may be utility for SNS01-T-like therapeutics in a range of human malignancies by making simple changes to customize our drug candidate for particular cancer types,’ stated Professor John Thompson, Ph.D., Chief Scientific Officer of Senesco. ‘Particularly striking is the observation that cancer cells take up more SNS01-T than normal cells and that the malignant cells are also more sensitive to the drug.’

SNS01-T was taken up by a series of B-cell tumor cell lines, including multiple myeloma, where uptake was up to 5-fold higher than uptake by normal naïve B cells. Uptake into myeloma cells induced ~ 45% cell death within 24 hours, whereas there was almost no measureable death of normal naïve B cells. Treatment with SNS01-T resulted in significant dose-dependent inhibition of tumor growth in animal models of multiple myeloma, mantle cell lymphoma and diffuse large B-cell lymphoma, with up to 85-90% inhibition at the highest doses. SNS01-T at ? 0.18 mg/kg significantly extended the life span of treated mice. There was also a reduction in the pro-survival form of the eIF5A protein in tumor tissue, consistent with drug activity. Finally, the combination of SNS01-T and lenalidomide (the active component of Revlimid) resulted in 100% survival of mice compared to 60% (SNS01-T) and 20% (lenalidomide) survival for either drug alone. Tumors were eradicated after a single 6-week cycle of the combination in 67% of the animals, and there was no regrowth after an additional 8 weeks without further treatment. Similarly, the combination of SNS01-T and bortezomib (the active component of Velcade) inhibited tumor growth by 89% compared to 59% (SNS01-T) and 39% (bortezomib) for either drug alone.”

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.  © 2014                                    The Hygiology Post ®